Compare NCLH & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCLH | DVA |
|---|---|---|
| Founded | 1966 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.1B |
| IPO Year | 2011 | 2002 |
| Metric | NCLH | DVA |
|---|---|---|
| Price | $19.80 | $156.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 4 |
| Target Price | $26.00 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 20.4M | 738.3K |
| Earning Date | 03-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.92 | ★ 9.84 |
| Revenue | $5,396,175,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $10.08 | $3.85 |
| Revenue Next Year | $6.60 | $3.07 |
| P/E Ratio | $22.00 | ★ $15.77 |
| Revenue Growth | ★ 10.71 | 6.46 |
| 52 Week Low | $14.21 | $101.00 |
| 52 Week High | $27.18 | $159.42 |
| Indicator | NCLH | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 64.58 |
| Support Level | $17.67 | $146.05 |
| Resistance Level | $20.15 | $158.31 |
| Average True Range (ATR) | 0.85 | 3.93 |
| MACD | 0.04 | -0.50 |
| Stochastic Oscillator | 46.15 | 93.52 |
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.